- Home
- PUBM vs ABUS Comparison
PUBM vs ABUS Comparison
Compare PUBM & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUBM
- ABUS
- Stock Information
- Founded
- PUBM 2006
- ABUS N/A
- Country
- PUBM United States
- ABUS United States
- Employees
- PUBM N/A
- ABUS N/A
- Industry
- PUBM Computer Software: Prepackaged Software
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- PUBM Technology
- ABUS Health Care
- Exchange
- PUBM Nasdaq
- ABUS Nasdaq
- Market Cap
- PUBM 732.4M
- ABUS 723.0M
- IPO Year
- PUBM 2020
- ABUS N/A
- Fundamental
- Price
- PUBM $15.30
- ABUS $4.12
- Analyst Decision
- PUBM Buy
- ABUS Strong Buy
- Analyst Count
- PUBM 7
- ABUS 4
- Target Price
- PUBM $21.17
- ABUS $5.25
- AVG Volume (30 Days)
- PUBM 332.8K
- ABUS 1.3M
- Earning Date
- PUBM 11-12-2024
- ABUS 11-05-2024
- Dividend Yield
- PUBM N/A
- ABUS N/A
- EPS Growth
- PUBM 351.34
- ABUS N/A
- EPS
- PUBM 0.36
- ABUS N/A
- Revenue
- PUBM $282,245,000.00
- ABUS $10,061,000.00
- Revenue This Year
- PUBM $10.76
- ABUS N/A
- Revenue Next Year
- PUBM $9.74
- ABUS N/A
- P/E Ratio
- PUBM $41.17
- ABUS N/A
- Revenue Growth
- PUBM 9.60
- ABUS N/A
- 52 Week Low
- PUBM $10.92
- ABUS $1.69
- 52 Week High
- PUBM $25.36
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- PUBM 55.82
- ABUS 57.68
- Support Level
- PUBM $14.55
- ABUS $3.68
- Resistance Level
- PUBM $15.50
- ABUS $4.35
- Average True Range (ATR)
- PUBM 0.43
- ABUS 0.14
- MACD
- PUBM 0.14
- ABUS 0.04
- Stochastic Oscillator
- PUBM 84.44
- ABUS 67.14
About PUBM PubMatic Inc.
PubMatic is one of the leading supply-side platform providers in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, better manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). PubMatic generates revenue mainly via taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Given the growth in overall digital advertising, more publishers and advertisers are adopting programmatic (or automated) buying and selling, driving the firm's success in attracting more inventory.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.